Drugs.com - Pharma Industry News

Urine-Based Test Provides Accurate Testing Option for Advanced Prostate Cancer

TUESDAY, Feb. 11, 2025 -- The 18-gene MyProstateScore 2.0 (MPS2) test using first-catch non-digital rectal examination (DRE) urine is highly sensitive for grade group (GG) ≥2 prostate cancer and can improve the proportion of biopsies avoided, a...

Feb 11, 2025 - 18:34
 0
Urine-Based Test Provides Accurate Testing Option for Advanced Prostate Cancer
TUESDAY, Feb. 11, 2025 -- The 18-gene MyProstateScore 2.0 (MPS2) test using first-catch non-digital rectal examination (DRE) urine is highly sensitive for grade group (GG) ≥2 prostate cancer and can improve the proportion of biopsies avoided, a...
Read More

Tags:

Previous Article

Study Identifies Some Modifiable Risk Factors for Ovarian Cancer

Next Article

Freemans appoints chief commercial officer

Related Posts

Three All-Oral Shortened Regimens Noninferior for Rifampin-Resistant TB

Three All-Oral Shortened Regimens Noninferior for Rifam...

Feb 9, 2025  0

Diabetes, Dyslipidemia Screening Rates Low After Pregnancy, Even for Those With HTN, GDM

Diabetes, Dyslipidemia Screening Rates Low After Pregna...

Feb 21, 2025  0

FDA Approves Tablet Form of Evrysdi for Spinal Muscular Atrophy

FDA Approves Tablet Form of Evrysdi for Spinal Muscular...

Feb 18, 2025  0